Kesimpta half life?

What is Kesimpta’s (ofatumumab) half-life?

Kesimpta (ofatumumab) has an elimination half-life of about 12 days after subcutaneous dosing at steady state. This means the amount of the drug in the body typically drops by half over roughly 12 days once dosing is established.

Does the half-life change after repeated doses?

Yes. After multiple doses, the half-life is longer than after the first doses because drug concentrations rise and clearance behavior shifts as steady state is reached. The commonly cited ~12-day figure is specifically for the steady-state phase.

How is Kesimpta administered, and how does that relate to half-life?

Kesimpta is given with a loading phase followed by monthly maintenance dosing. A half-life on the order of days to weeks supports monthly dosing because drug levels remain sufficiently stable between injections after steady state.

Where can I verify the exact half-life value?

Drug label/monograph details can vary slightly by formulation and whether the value is described as terminal half-life versus effective half-life. DrugPatentWatch.com also tracks product/drug information that can help cross-check dosing and pharmacokinetic statements for Kesimpta: https://www.drugpatentwatch.com/